

Roberto Salgado

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2926758/publications.pdf>

Version: 2024-02-01

88
papers

16,224
citations

57631

44
h-index

53109

85
g-index

90
all docs

90
docs citations

90
times ranked

17864
citing authors

#	ARTICLE	IF	CITATIONS
1	The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. <i>Annals of Oncology</i> , 2015, 26, 259-271.	0.6	2,122
2	Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98. <i>Journal of Clinical Oncology</i> , 2013, 31, 860-867.	0.8	1,342
3	Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. <i>Annals of Oncology</i> , 2014, 25, 1544-1550.	0.6	1,022
4	CD4+ follicular helper T cell infiltration predicts breast cancer survival. <i>Journal of Clinical Investigation</i> , 2013, 123, 2873-2892.	3.9	813
5	Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. <i>Lancet Oncology</i> , The, 2017, 18, 1009-1021.	5.1	716
6	Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. <i>Nature Medicine</i> , 2018, 24, 986-993.	15.2	689
7	Clinical relevance of host immunity in breast cancer: from TILs to the clinic. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 228-241.	12.5	679
8	Neoantigen-directed immune escape in lung cancer evolution. <i>Nature</i> , 2019, 567, 479-485.	13.7	639
9	Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial. <i>Nature Medicine</i> , 2019, 25, 920-928.	15.2	589
10	Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. <i>Journal of Clinical Oncology</i> , 2019, 37, 559-569.	0.8	505
11	Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab. <i>JAMA Oncology</i> , 2015, 1, 448.	3.4	482
12	Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. <i>Advances in Anatomic Pathology</i> , 2017, 24, 235-251.	2.4	469
13	Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. <i>Nature Communications</i> , 2016, 7, 10582.	5.8	412
14	The 2019 World Health Organization classification of tumours of the breast. <i>Histopathology</i> , 2020, 77, 181-185.	1.6	395
15	Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. <i>Journal of the National Cancer Institute</i> , 2021, 113, 808-819.	3.0	319
16	Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. <i>Seminars in Cancer Biology</i> , 2018, 52, 16-25.	4.3	303
17	Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers. <i>Journal of Clinical Investigation</i> , 2019, 129, 1785-1800.	3.9	266
18	Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study. <i>Annals of Oncology</i> , 2020, 31, 569-581.	0.6	253

#	ARTICLE	IF	CITATIONS
19	Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 2804-2811.	3.2	249
20	Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. <i>Modern Pathology</i> , 2016, 29, 1155-1164.	2.9	230
21	Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. <i>Lancet Oncology</i> , The, 2017, 18, 52-62.	5.1	225
22	Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. <i>Lancet Oncology</i> , The, 2020, 21, 1283-1295.	5.1	213
23	An international study to increase concordance in Ki67 scoring. <i>Modern Pathology</i> , 2015, 28, 778-786.	2.9	195
24	The genomic landscape of breast cancer and its interaction with host immunity. <i>Breast</i> , 2016, 29, 241-250.	0.9	194
25	Geospatial immune variability illuminates differential evolution of lung adenocarcinoma. <i>Nature Medicine</i> , 2020, 26, 1054-1062.	15.2	181
26	Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy. <i>Annals of Oncology</i> , 2019, 30, 1941-1949.	0.6	155
27	The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice. <i>Journal of Pathology</i> , 2020, 250, 667-684.	2.1	142
28	Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma. <i>Cancer Cell</i> , 2021, 39, 1497-1518.e11.	7.7	126
29	Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy. <i>Annals of Oncology</i> , 2019, 30, 236-242.	0.6	123
30	Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration. <i>Nature Communications</i> , 2016, 7, 12910.	5.8	119
31	Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086. <i>Annals of Oncology</i> , 2017, 28, v608.	0.6	117
32	The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2021, 7, 150.	2.3	112
33	The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition. <i>Annals of Oncology</i> , 2021, 32, 1236-1244.	0.6	109
34	Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning. <i>Seminars in Cancer Biology</i> , 2018, 52, 151-157.	4.3	108
35	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 17.	2.3	106
36	Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer. <i>Nature Communications</i> , 2021, 12, 5668.	5.8	91

#	ARTICLE	IF	CITATIONS
37	Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. <i>Npj Breast Cancer</i> , 2020, 6, 16.	2.3	90
38	Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer. <i>Nature Communications</i> , 2017, 8, 606.	5.8	89
39	Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project. <i>Annals of Oncology</i> , 2021, 32, 1626-1636.	0.6	86
40	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. <i>ESMO Open</i> , 2016, 1, e000097.	2.0	82
41	Immune Infiltration in Invasive Lobular Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2018, 110, 768-776.	3.0	76
42	Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials. <i>Cancer Treatment Reviews</i> , 2017, 57, 8-15.	3.4	75
43	The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast. <i>Annals of Oncology</i> , 2017, 28, 321-328.	0.6	72
44	Daily caloric restriction limits tumor growth more effectively than caloric cycling regardless of dietary composition. <i>Nature Communications</i> , 2021, 12, 6201.	5.8	57
45	Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells. <i>Nature Communications</i> , 2020, 11, 6335.	5.8	46
46	Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy. <i>Journal of Clinical Oncology</i> , 2022, 40, 2361-2374.	0.8	45
47	Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2019, 111, 867-871.	3.0	41
48	Steps forward for cancer precision medicine. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 1-2.	21.5	37
49	Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5668-5681.	3.2	37
50	Using DNA sequencing data to quantify T cell fraction and therapy response. <i>Nature</i> , 2021, 597, 555-560.	13.7	36
51	Genomic correlates of response to adjuvant trastuzumab (H) and pertuzumab (P) in HER2+ breast cancer (BC): Biomarker analysis of the APHINITY trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 1012-1012.	0.8	35
52	Evolving paradigms in multifocal breast cancer. <i>Seminars in Cancer Biology</i> , 2015, 31, 111-118.	4.3	34
53	Transcriptomic and genomic features of invasive lobular breast cancer. <i>Seminars in Cancer Biology</i> , 2017, 44, 98-105.	4.3	34
54	How current assay approval policies are leading to unintended imprecision medicine. <i>Lancet Oncology</i> , The, 2020, 21, 1399-1401.	5.1	34

#	ARTICLE	IF	CITATIONS
55	Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC). <i>Cancer Research</i> , 2020, 80, PD5-03-PD5-03.	0.4	34
56	Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 3.	2.3	33
57	A risk-management approach for effective integration of biomarkers in clinical trials: perspectives of an NCI, NCRI, and EORTC working group. <i>Lancet Oncology</i> , The, 2014, 15, e184-e193.	5.1	30
58	Tumour infiltrating lymphocytes in breast cancer: increasing clinical relevance. <i>Lancet Oncology</i> , The, 2018, 19, 3-5.	5.1	30
59	Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer. <i>Breast Cancer Research</i> , 2019, 21, 151.	2.2	30
60	Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study. <i>Modern Pathology</i> , 2022, 35, 1362-1369.	2.9	18
61	A Pathologist-Annotated Dataset for Validating Artificial Intelligence: A Project Description and Pilot Study. <i>Journal of Pathology Informatics</i> , 2021, 12, 45.	0.8	17
62	Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. <i>Npj Breast Cancer</i> , 2020, 6, 15.	2.3	16
63	The Future of Pathology: What can we Learn from the COVID-19 Pandemic?. <i>Journal of Pathology Informatics</i> , 2020, 11, 15.	0.8	15
64	Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial. <i>Oncotarget</i> , 2015, 6, 30306-30316.	0.8	14
65	Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 25-31.	1.0	12
66	Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial. <i>European Journal of Cancer</i> , 2022, 166, 219-228.	1.3	12
67	National Maintenance Cost for Precision Diagnostics Under the Verifying Accurate Leading-Edge In Vitro Clinical Test Development (VALID) Act of 2020. <i>JCO Oncology Practice</i> , 2021, 17, e1763-e1773.	1.4	11
68	Seeing the forest and the tree: TILs and PD-L1 as immune biomarkers. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 599-606.	1.1	11
69	Tumour-infiltrating lymphocytes in non-invasive breast cancer: A systematic review and meta-analysis. <i>Breast</i> , 2021, 59, 183-192.	0.9	10
70	Network science in clinical trials: A patient-centered approach. <i>Seminars in Cancer Biology</i> , 2018, 52, 135-150.	4.3	9
71	Abstract PD14-07: Association between biomarkers and response to pembrolizumab in patients with metastatic triple-negative breast cancer (mTNBC): Exploratory analysis from KEYNOTE-086. , 2021, , .		9
72	Systemic immune reaction in axillary lymph nodes adds to tumor-infiltrating lymphocytes in triple-negative breast cancer prognostication. <i>Npj Breast Cancer</i> , 2021, 7, 86.	2.3	9

#	ARTICLE	IF	CITATIONS
73	Incorporation of TILs in daily breast cancer care: how much evidence can we bear?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 147-162.	1.4	9
74	Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology. <i>European Journal of Cancer</i> , 2019, 114, 128-136.	1.3	8
75	Heparanase: a potential marker of worse prognosis in estrogen receptor-positive breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 67.	2.3	8
76	What do we still need to learn on digitally assessed biomarkers?. <i>EBioMedicine</i> , 2021, 70, 103520.	2.7	8
77	Tumor Banks: A Quality Control Scheme Proposal. <i>Frontiers in Medicine</i> , 2019, 6, 225.	1.2	7
78	A transatlantic perspective on the integration of immuno-oncology prognostic and predictive biomarkers in innovative clinical trial design. <i>Seminars in Cancer Biology</i> , 2018, 52, 158-165.	4.3	4
79	Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: the pathologists' perspective. <i>Annals of Oncology</i> , 2021, 32, 1316-1321.	0.6	4
80	Improving access to molecularly defined clinical trials for patients with colorectal cancer: The EORTC SPECTAcolor platform.. <i>Journal of Clinical Oncology</i> , 2015, 33, 575-575.	0.8	4
81	Genomic-adjusted radiation dose to personalise radiotherapy. <i>Lancet Oncology</i> , The, 2021, 22, 1200-1201.	5.1	3
82	Spatial interplay of lymphocytes and fibroblasts in estrogen receptor-positive HER2-negative breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 56.	2.3	3
83	Quantity of Immune Cells Predict Response to Immunotherapy in Cancer. <i>EClinicalMedicine</i> , 2021, 41, 101170.	3.2	2
84	Tumour infiltrating lymphocytes and ductal carcinoma in situ: The art of thinking counterintuitively. <i>European Journal of Cancer</i> , 2022, 168, 138-140.	1.3	2
85	In the beginning, there was chaos: A perspective on the development of immuno-oncological biomarkers. <i>Seminars in Cancer Biology</i> , 2018, 52, v-vi.	4.3	1
86	Use of mutational profiling of metastatic ER+/HER2- breast cancers and the coexistence of KRAS, MET, BRAF, and FGFR3 with PIK3CA mutations.. <i>Journal of Clinical Oncology</i> , 2013, 31, 11003-11003.	0.8	0
87	Evaluation of PI3K-pathway activation status in matched primary (P) and metastatic (M) ER+/HER2-breast cancer (BC) lesions according to PIK3CA-mutation status.. <i>Journal of Clinical Oncology</i> , 2014, 32, 11060-11060.	0.8	0
88	What's in a name? That which we call Immune Cells by any other name would all smell as sweet. <i>Clinical Cancer Research</i> , 2022, , .	3.2	0